Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2019

View Archived Issues

Suzhou Yunxuan Yiyao Keji Youxian Gongsi discloses CXCR4 antagonists

Why there's no Emgality equality

Combination approach could foil pancreatic tumors

Discovery of novel DS-6930 derivatives by structure-activity relationship analysis

Chemerin involved in tumorigenesis and metastasis of OSCC and may be useful as a serum biomarker

TTC21A biallelic mutations induce asthenoteratospermia

Novel isocytosine deaminase Vcz converts 5-FIC prodrug into toxic 5-FU for cancer therapy

OPKO reports additional phase II results for OPK-88003 in patients with diabetes and obesity

Gilead Sciences and Novo Nordisk to collaborate on clinical trial in NASH

Growth acceleration seen with maralixibat in progressive familial intrahepatic cholestasis

Odevixibat has beneficial effects in phase II trials in Alagille syndrome, biliary atresia

FDA approves Balversa for metastatic bladder cancer

Potential new regenerative strategy identified for OA

Dragonfly Therapeutics patents proteins binding NKG2D, CD16 and a tumor-associated antigen

Ionis Pharmaceuticals synthesizes oligonucleotides targeting Smad7

New data presented from phase III CREDENCE study

CDK19 inhibitors discovered by Stanford University, Chan Zuckerberg Biohub

U.S. Department of Health & Human Services, Lentigen Technology describe CAR T cells targeting CD19

PCAT1 identified as a potential therapeutic target in HNSCC

Sunshine Lake Pharma initiates phase I study of HEC-110114 tablets

Harpoon Therapeutics recruiting patients in phase I/II study of HPN-536

Sorrento Therapeutics expands clinical development program for resiniferatoxin

Zymeworks initiates phase II study of ZW-25 in HER2-expressing metastatic gastroesophageal cancers

First patient dosed in global phase II/III ILLUMINATE study of sepofarsen for LCA10

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...